Sorafenib in advanced clear-cell renal-cell carcinoma.

By B. Escudier, T. Eisen, W. Stadler, C. Szczylik, S. Oudard, M. Siebels, S. Négrier, C. Chevreau, E. Solska, A. Desai and 9 more. New England Journal of Medicine, 2007

4,849 citations recorded by the source corpus.

Subfields: Oncology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/8cec69c030e7230c14ffeb5942a04dd63416177e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Rakesh K. Jain
2. N. Ferrara
3. D. McDonald
4. Stephen J. Elledge
5. B. Larrivée
6. C. Viallard
7. A. Adamis
8. N. Vasudev

In Pathology and Forensic Medicine

1. Ji Luo
2. Rakesh K. Jain
3. Stephen J. Elledge
4. B. Larrivée
5. C. Viallard
6. N. Solimini

In Pulmonary and Respiratory Medicine

1. Rakesh K. Jain
2. Stephen J. Elledge
3. B. Rini
4. M. C. Simon
5. N. Ferrara
6. B. Larrivée
7. C. Viallard
8. Pengfei Lu

Citations in the corpus

• Ten years of anti-vascular endothelial growth factor therapy (2016, background): “The Phase III TARGET study in patients with metastatic renal cell carcinoma reported that sorafenib increased the median PFS 111 and OS 20 .”
• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “95) 3 [127]”
• Phase 3 trial of everolimus for metastatic renal cell carcinoma (2010, background): “The adverse event profile of everolimus differs from that of VEGFR-TKIs.(12,13) This may be an advantage in patients showing intolerance to sorafenib or sunitinib and could avoid potential for cumulative toxicity associated with sequential VEGFR-TKI treatment.”
• Angiogenic signaling pathways and anti-angiogenic therapy for cancer (2023, background): “8 months) alone (NCT00073307).(410) However, the toxicity increased a lot due to the pan-inhibition of multiple kinases.”
• EAU guidelines on renal cell carcinoma: 2014 update. (2010, neutral): “The trial reported a 3-mo improvement in progression-free survival in favour of sorafenib [43].”
• Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction (2009, positive): “Additionally, the small-molecule inhibitors sorafenib and sunitinib, which target multiple receptor tyrosine kinases including VEGF receptors, have shown efficacy in treating metastatic renal cell carcinoma (Escudier et al., 2007; Motzer et al., 2006).”
• ANTIANGIOGENESIS STRATEGIES REVISITED: FROM STARVING TUMORS TO ALLEVIATING HYPOXIA (2014, positive): “Bevacizumab IFN-a2A metastatic RCC [ progression-free survival (Escudier et al., 2010)”
• The impact of O2 availability on human cancer (2008, background): “aspx?CdrID=299013">sorafenib (Nexavar, Bayer), which has shown clinical benefit in renal and hepatocellular carcinom”